{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:14:58Z","timestamp":1792224898647,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Scabies is a pruritic parasitic infestation of the skin. High-income countries have reported an increasing incidence over the last few years. Studies have indicated a reduction in the sensitivity of scabies mites to the standard treatment of choice, topical permethrin 5%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate in a head-to-head manner the efficacy of two topical scabicides [permethrin 5% and benzyl benzoate 25% (BB)] in the treatment of scabies using the same administration modality; and to address potential confounding factors such as incorrectly performed treatment and hygiene measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In total, 110 patients with dermoscopy-verified scabies infestation were enrolled and randomized into two equally sized groups in a double-blinded manner. Fifty-five received topical permethrin 5% and 55 received topical BB 25%, both for daily use over a period of three consecutive days. Treatment outcome was evaluated by dermoscopy at a 3-week follow-up visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Treatment resulted in a dermoscopy-verified cure rate of 27% in the permethrin group and 87% in the BB group. The tolerability and safety profile of permethrin 5% cream was excellent, while the BB emulsion produced a burning sensation in 43% of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Topical permethrin demonstrated a lack of efficacy in the majority of scabies cases, whereas BB demonstrated an excellent cure rate and reasonable tolerability. Considering the reduced sensitivity of scabies mites to permethrin 5%, our results suggest that BB is an appropriate first-line therapy in the treatment of scabies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad501","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:09:14Z","timestamp":1703002154000},"page":"486-491","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-6917","authenticated-orcid":false,"given":"Damian","family":"Meyersburg","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-4041","authenticated-orcid":false,"given":"Magdalena","family":"Hoellwerth","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brandlmaier","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allesandra","family":"Handisurya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Psychosomatics and Inpatient Psychotherapy, University Hospital of Psychiatry and Psychotherapy, Paracelsus Medical University , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Prodinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-9170","authenticated-orcid":false,"given":"Johann W","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2024031513100878500_ljad501-B1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjd.18943","article-title":"The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies","volume":"183","author":"Engelman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024031513100878500_ljad501-B2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/22221751.2020.1754136","article-title":"Trends in prevalence and incidence of scabies from 1990 to 2017: findings from the Global Burden of Disease study 2017","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2024031513100878500_ljad501-B3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006996","article-title":"Exploration of a simplified clinical examination for scabies to support public health decision-making","volume":"12","author":"Marks","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024031513100878500_ljad501-B4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3201\/eid2706.203681","article-title":"Reemergence of scabies driven by adolescents and young adults, Germany, 2009\u20132018","volume":"27","author":"Reichert","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2024031513100878500_ljad501-B5","first-page":"15","article-title":"Increase of \u00adscabies\u00a0in Germany and development of resistant mites? Evidence and consequences","volume":"17","author":"Sunderk\u00f6tter","year":"2019","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"2024031513100878500_ljad501-B6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00105-020-04608-0","article-title":"Anstieg von Skabies und Therapierefrakt\u00e4rit\u00e4t bei Bundeswehrangeh\u00f6rigen: Acht-Jahre-Follow-up-Studie aus der Hautklinik des Bundeswehrkrankenhauses Berlin (2012\u20132019)","volume":"71","author":"Elsner","year":"2020","journal-title":"Hautarzt"},{"key":"2024031513100878500_ljad501-B7","doi-asserted-by":"crossref","first-page":"18599","DOI":"10.1111\/jdv.18599","article-title":"Prescriptions for scabies are rapidly increasing in Spain: an ecological study with national prescription data, 2008\u20132021","volume":"37","author":"Mart\u00ednez-Garc\u00eda","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268865","article-title":"Increasing incidence of reported scabies infestations in the Netherlands, 2011\u20132021","volume":"17","author":"Van Deursen","year":"2022","journal-title":"PLOS ONE"},{"key":"2024031513100878500_ljad501-B9","doi-asserted-by":"crossref","first-page":"190020","DOI":"10.2807\/1560-7917.ES.2019.24.23.190020","article-title":"Increase of scabies \u00adinfestations, Norway, 2006 to 2018","volume":"24","author":"Amato","year":"2019","journal-title":"Eurosurveillance"},{"key":"2024031513100878500_ljad501-B10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/jdv.14351","article-title":"European guideline for the management of scabies","volume":"31","author":"Salavastru","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jaad.2019.01.004","article-title":"Efficacy and safety of antiscabietic agents: a systematic review and network meta-analysis of randomized controlled trials","volume":"80","author":"Thadanipon","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024031513100878500_ljad501-B12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/1346-8138.13896","article-title":"Guideline for the diagnosis and treatment of scabies in Japan (third edition): Executive Committee of Guideline for the Diagnosis and Treatment of Scabies","volume":"44","author":"Executive Committee of Guideline for the Diagnosis and Treatment of Scabies","year":"2017","journal-title":"J Dermatol"},{"key":"2024031513100878500_ljad501-B13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jamadermatol.2019.0279","article-title":"Evaluation of ivermectin vs permethrin for treating scabies \u2013 summary of a Cochrane review","volume":"155","author":"Rosumeck","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2024031513100878500_ljad501-B14","first-page":"757","article-title":"The treatment of scabies","volume":"113","author":"Dressler","year":"2016","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2024031513100878500_ljad501-B15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1472-8206.2003.00173.x","article-title":"Current treatments for scabies","volume":"17","author":"Buffet","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"2024031513100878500_ljad501-B16","first-page":"CD000320","article-title":"Interventions for treating scabies","volume":"2007","author":"Strong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2024031513100878500_ljad501-B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.annder.2015.10.588","article-title":"Gales en \u00e9chec de traitement: \u00e9tude observationnelle","volume":"143","author":"De Sainte Marie","year":"2016","journal-title":"Ann Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B18","doi-asserted-by":"crossref","first-page":"e0005920","DOI":"10.1371\/journal.pntd.0005920","article-title":"Scabies in the age of increasing drug resistance","volume":"11","author":"Khalil","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2024031513100878500_ljad501-B19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ad.2022.07.017","article-title":"Epidemic scabies: new treatment challenges in an ancient disease","volume":"114","author":"Lluch-Galcer\u00e1","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"2024031513100878500_ljad501-B20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/09546634.2020.1774489","article-title":"Loss of efficacy of topical 5% permethrin for treating scabies: an Austrian single-center study","volume":"33","author":"Meyersburg","year":"2022","journal-title":"J Dermatol Treat"},{"key":"2024031513100878500_ljad501-B21","doi-asserted-by":"crossref","first-page":"17339","DOI":"10.1111\/jdv.17339","article-title":"Is scabies becoming less sensitive to permethrin therapy?","volume":"35","author":"Mazzatenta","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B22","doi-asserted-by":"crossref","first-page":"17538","DOI":"10.1111\/jdv.17538","article-title":"Scabies is becoming less sensitive to permethrin therapy","volume":"35","author":"Balestri","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/idr15020023","article-title":"Study of the use of permethrin 5% cream in Galicia (Spain) between 2018 and 2021","volume":"15","author":"V\u00e1zquez-Prieto","year":"2023","journal-title":"Infect Dis Rep"},{"key":"2024031513100878500_ljad501-B24","doi-asserted-by":"crossref","first-page":"15897","DOI":"10.1111\/dth.15897","article-title":"Comparison of sulfur ointment and permethrin treatments in scabies","volume":"35","author":"Ertugrul","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024031513100878500_ljad501-B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00105-021-04783-8","article-title":"Skabies \u2013 klinische Therapieresistenz auf Permethrin: Fallbeschreibungen und eine kritische Auseinandersetzung mit den aktuellen Therapieempfehlungen","volume":"72","author":"Mang","year":"2021","journal-title":"Hautarzt"},{"key":"2024031513100878500_ljad501-B26","doi-asserted-by":"crossref","first-page":"18181","DOI":"10.1111\/jdv.18181","article-title":"European scabies challenge: what about permethrin-resistant mites?","volume":"36","author":"Mayer","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B27","doi-asserted-by":"crossref","first-page":"102545","DOI":"10.1016\/j.tmaid.2023.102545","article-title":"A resistant parasitic flare-up amid children in Italy: Comment on \u2018Diagnosis and\u00a0management of pediatric scabies: results from a survey on 317 Italian dermatologists\u2019","volume":"52","author":"Herzum","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"2024031513100878500_ljad501-B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpeds.2022.02.016","article-title":"Comparison of permethrin-based treatment strategies against scabies in infants and young children","volume":"245","author":"Riebenbauer","year":"2022","journal-title":"J Pediatr"},{"key":"2024031513100878500_ljad501-B29","doi-asserted-by":"crossref","first-page":"15495","DOI":"10.1111\/dth.15495","article-title":"Use of oral ivermectin in permethrin-resistant scabies: a pilot study","volume":"35","author":"Balestri","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024031513100878500_ljad501-B30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.23736\/S0392-0488.16.05404-3","article-title":"A new treatment regimen with permethrin in scabies","volume":"153","author":"Veraldi","year":"2018","journal-title":"Ital J Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s15012-021-6813-7","article-title":"Was tun bei (therapieresistenter) Skabies","volume":"38","author":"Schaller","year":"2022","journal-title":"Hautnah Dermatol"},{"key":"2024031513100878500_ljad501-B32","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1111\/jdv.18026","article-title":"Topical ivermectin: an off-label alternative to treat neonatal Scabies in the era of permethrin resistance","volume":"36","author":"Bassi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B33","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/jdv.19288","article-title":"Detection of a knockdown mutation in the voltage-sensitive sodium channel associated with permethrin tolerance in Sarcoptes scabiei var. hominis mites","volume":"37","author":"Riebenbauer","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024031513100878500_ljad501-B34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00105-020-04561-y","article-title":"Skabiestherapie in Deutschland: Ergebnisse einer bundesweiten Umfrage mit besonderem Fokus auf die Wirksamkeit der Erstlinientherapie mit Permethrin","volume":"71","author":"Hackenberg","year":"2020","journal-title":"Hautarzt"},{"key":"2024031513100878500_ljad501-B35","first-page":"695","article-title":"Scabies: epidemiology, diagnosis, and treatment","volume":"118","author":"Sunderk\u00f6tter","year":"2021","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2024031513100878500_ljad501-B36","first-page":"554","article-title":"Application errors associated with topical treatment of scabies: an observational study","volume":"18","author":"Nemecek","year":"2020","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"2024031513100878500_ljad501-B37","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","article-title":"Mass drug administration for scabies control in a population with endemic disease","volume":"373","author":"Romani","year":"2015","journal-title":"N Engl J Med"},{"key":"2024031513100878500_ljad501-B38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJMc1808439","article-title":"Mass drug administration for scabies \u2013 2\u2005years of follow-up","volume":"381","author":"Romani","year":"2019","journal-title":"N Engl J Med"},{"key":"2024031513100878500_ljad501-B39","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/ddg.13130","article-title":"S1 guidelines on the diagnosis and treatment of scabies \u2013 short version","volume":"14","author":"Sunderk\u00f6tter","year":"2016","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"2024031513100878500_ljad501-B40","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1001\/archdermatol.2008.513","article-title":"Treating scabies: results from an updated Cochrane review","volume":"144","author":"Hu","year":"2008","journal-title":"Arch Dermatol"},{"key":"2024031513100878500_ljad501-B41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jdv.18573","article-title":"Comparison of topical\u00a0benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study","volume":"37","author":"Meyersburg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad501\/56618083\/ljad501.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/486\/56986134\/ljad501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/486\/56986134\/ljad501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:10:58Z","timestamp":1710508258000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/4\/486\/7478651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad501","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,12,19]]}}}